Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Recursion Pharmaceuticals
Biotech
BMS removes 2 clinical programs from pipeline
BMS is shedding two clinical programs from its wholly owned pipeline, one from its Mirati buyout and another from a partnership with Exscientia.
Gabrielle Masson
Oct 30, 2025 1:14pm
Rallybio shifts gears, cashing out of Recursion pact
Jul 8, 2025 8:59am
Recursion lays off 20% of staff in wake of pipeline cutbacks
Jun 10, 2025 9:25am
Recursion streamlines pipeline following merger with Exscientia
May 5, 2025 11:00am
Former FDA deputy joins AI biotech's board—Chutes & Ladders
Mar 21, 2025 8:30am
Altitude sources funding for biotechs concerned about NIH grants
Feb 19, 2025 1:00pm
